Abstract 5673
Background
Lung cancer is the leading cancer-related death disease worldwide. This alerting data is mainly due to late diagnosis of lung cancer, especially non-small cell-lung cancer (NSCLC), limiting the therapeutic options. Therefore, the identification of non-invasive, selective, sensitive and specific biomarker/s represents the emerging medical need for the clinical practice to avoid late diagnosis and ameliorate the personalized therapy with an ensuing higher survival rate. It is well known that smoking and chronic obstructive pulmonary disease represent two high risk factors for NSCLC. Therefore, in this study we aimed to evaluate the levels of a novel diagnostic tool for NSCLC patients in order to understand whether caspase-4 could represent a predictive biomarker.
Methods
In order to evaluate the circulating caspase-4 in the blood, we developed an ELISA test.
Results
Smokers (≥15 cigarettes/day) had higher levels of circulating caspase-4 (95% CI, 1.331-1.94 ng/ml) than healthy subjects (95% CI, 0.395-0.619 ng/ml). Though, these levels were statistically lower than those observed in NSCLC patients. Moreover, there were no statistical differences between the levels of circulating caspase-4 in smokers younger or older than 60 years. Similarly, no gender differences were noted. Similarly, COPD patients, who are smokers and former smokers, had higher levels of circulating caspase-4 (95% CI, 1.703-2.995 ng/ml). According to χ2 test, the expected frequency of smokers, positive to the circulating caspase-4, who could develop NSCLC is robustly significant (calculated χ2=82.884 vs tabulated χ2=3.845, df = 1). Moreover, according to the independence test, smoker who were positive to the circulating caspase-4 are at high risk to develop NSCLC.
Conclusions
In conclusion, we report for the first time that the circulating caspase-4 could represent a predictive diagnostic tool to avoid the occurrence of NSCLC.
Clinical trial identification
Legal entity responsible for the study
ImmunePharma s.r.l.
Funding
Italian Ministry of Economy (MISE) Invitalia.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract